Pharma and Biotech Daily: Your Daily Dose of What's Important in the Industry

Pharma and BioTech Daily

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. The CEO of 23andme, Anne Wojcicki, has proposed to take the company private by buying shares at 40 cents each. GE Healthcare is facing pressure in China as hospitals delay orders, impacting revenue growth for Johnson & Johnson and Philips as well. The FDA and Health Canada are working together to raise awareness of a recall for J&J's Megadyne electrode pads. Stryker plans to be very active in mergers and acquisitions and is launching an orthopedic robot in the second half of the year. Labcorp is expanding its partnership with Ultima Genomics to boost genomic diagnostics by using a machine designed to sequence the genome for $100.Transitioning to the next segment, Moderna's shares fell due to a lower sales outlook for their RSV and COVID shots, while Otsuka acquired startup Jnana in a deal worth $800 million. Biogen is optimistic about the future of their Alzheimer's drug, Leqembi, and Cigna's CEO promises a strong defense of pharmacy benefit managers. The biotech M&A market is on the rise, with Otsuka's acquisition of Jnana being the 16th deal for a private startup with at least $50 million upfront. The industry is also exploring the use of eClinical technologies in research to improve efficiency. Overall, the biopharma sector is experiencing significant developments and changes that are shaping the industry landscape.Moving on to the following update, Moderna's stock price plummeted over 20% after the company reduced its revenue guidance for 2024 due to decreased demand for its COVID-19 vaccine in the second quarter. Meanwhile, Lilly's tirzepatide successfully cleared a Phase III cardiovascular study, showing a 38% reduction in heart failure risk. Otsuka Pharmaceutical is acquiring Jnana Therapeutics for up to $1.1 billion, adding to its drug discovery capabilities. The FDA is questioning the evidence supporting Zevra's rare disease therapy ahead of an advisory committee meeting. Novo Nordisk lost a legal case regarding price negotiations, while Sanofi sued Sarepta over alleged patent infringement.Shifting gears to marketing news, Carter's is targeting Gen Z parents by focusing on more than just cute clothing, with insights and strategy from CMO Jeff Jenkins. Meta is utilizing AI to automate creative and personalize ads in real time, leading to a 22% increase in revenue. Hyundai has split the CMO role into creative and performance positions, with Angela Zepeda becoming Chief Creative Officer. Shapermint's proprietary AI ad tool, Altair, has helped streamline content production and attract new customers. Additionally, the role of print in marketing strategies is explored in a webinar, and tips for creating successful loyalty programs are shared.Finally, pharma executives are turning their attention to health equity and increasing diversity in clinical trials. A trendline explores strategies to boost diversity in trials. While business literature like "The First 90 Days" by Michael Watkins helps with career moves, real-life medical thrillers like "Last Night in the OR" and "Empire of Pain" offer insights into healthcare and pharma. Six books that pharma execs swear by are also highlighted. Pfizer's CEO remains confident in the company's position in the obesity drug market, despite delays. The newsletter also covers inflation penalties for big pharma companies, the potential impact of a combo COVID/flu shot on vaccinations, and best practices for new drug applications and biologics license applications.That's all for today on Pharma and Biotech daily - bringing you the latest updates and insights from the world of pharmaceuticals and biotechnology.

Support the Show.